Neurodegenerative Program

About Helixomer

Helixomer is a private, preclinical biotech firm pioneering a novel drug design platform that combines RNA origami (RNAO) with aptamers to create more effective nanodrugs. Its core technology aims to overcome the historical limitations of aptamers—such as low efficacy and rapid clearance—by arranging multiple aptamers on a stable, non-immunogenic RNA scaffold. The company is applying this modular, 'plug-and-play' platform to build a pipeline in oncology, neurodegenerative disorders, and cardiovascular disease, positioning itself as a next-generation RNA medicine developer.

Therapeutic Areas